Traders sold shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) on strength during trading on Tuesday. $48.42 million flowed into the stock on the tick-up and $58.00 million flowed out of the stock on the tick-down, for a money net flow of $9.58 million out of the stock. Of all companies tracked, Vertex Pharmaceuticals had the 0th highest net out-flow for the day. Vertex Pharmaceuticals traded up $0.94 for the day and closed at $99.14

Several research firms recently issued reports on VRTX. Robert W. Baird reiterated an “outperform” rating and issued a $128.00 price objective (down previously from $144.00) on shares of Vertex Pharmaceuticals in a report on Sunday, May 1st. Maxim Group reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, April 28th. Cowen and Company reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, July 28th. BMO Capital Markets began coverage on Vertex Pharmaceuticals in a research note on Thursday, April 7th. They set a “market perform” rating and a $90.00 target price for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, April 28th. Nine analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $120.57.

The stock has a 50 day moving average of $89.78 and a 200-day moving average of $87.38. The firm’s market cap is $24.56 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.03. The firm had revenue of $431.61 million for the quarter, compared to the consensus estimate of $428.08 million. During the same period in the previous year, the firm earned ($0.54) EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 159.9% on a year-over-year basis. On average, equities analysts expect that Vertex Pharmaceuticals Inc. will post $1.02 EPS for the current fiscal year.

In related news, SVP Paul M. Silva sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $87.63, for a total transaction of $262,890.00. Following the sale, the senior vice president now owns 15,950 shares of the company’s stock, valued at $1,397,698.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Joshua S. Boger sold 5,130 shares of the business’s stock in a transaction that occurred on Wednesday, May 18th. The stock was sold at an average price of $81.18, for a total value of $416,453.40. Following the sale, the director now directly owns 270,414 shares in the company, valued at approximately $21,952,208.52. The disclosure for this sale can be found here.

A number of large investors have recently made changes to their positions in the company. BlackRock Investment Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 41.2% in the fourth quarter. BlackRock Investment Management LLC now owns 1,518,732 shares of the pharmaceutical company’s stock valued at $191,102,000 after buying an additional 443,445 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Vertex Pharmaceuticals by 158.6% in the fourth quarter. Marshall Wace LLP now owns 241,824 shares of the pharmaceutical company’s stock valued at $30,428,000 after buying an additional 148,314 shares during the last quarter. BlackRock Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 8.5% in the fourth quarter. BlackRock Advisors LLC now owns 1,851,260 shares of the pharmaceutical company’s stock valued at $232,944,000 after buying an additional 144,624 shares during the last quarter. Morgan Stanley boosted its stake in shares of Vertex Pharmaceuticals by 57.0% in the fourth quarter. Morgan Stanley now owns 309,826 shares of the pharmaceutical company’s stock valued at $38,986,000 after buying an additional 112,441 shares during the last quarter. Finally, Employees Retirement System of Texas boosted its stake in shares of Vertex Pharmaceuticals by 41.5% in the fourth quarter. Employees Retirement System of Texas now owns 92,000 shares of the pharmaceutical company’s stock valued at $11,576,000 after buying an additional 27,000 shares during the last quarter.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.